HUMAN IL-2 ??

HUMAN IL-2 C??? ??, ??, ??

??

Antineoplastic; biological response modifier; immunostimulant.

Indications

Aldesleukin (IL-2, Proleukin) is a human recombinant interleukin-2 protein. Its antitumor action is thought to include multiple effects on the immune system, such as enhancement of T-lymphocyte cytotoxicity, induction of natural killer cell activity, and induction of interferon-γ production. Aldesleukin has been used alone and in combination with lymphokine activated killer (LAK) cells or tumor-infiltrating lymphocytes (TIL).
The drug produces remissions in 15% of patients with renal cell carcinoma, with median durations of remission of 18 to 24 months.

?? ??

Aldesleukin, T-cell growth factor, thymocyte-stimulatingfactor, Proleukin, is recombinant IL-2 expressed in an engineeredstrain of E. coli containing an analog of the humanIL-2 gene.Aldesleukin enhances lymphocyte mitogenesis and stimulateslong-term growth of human IL-2-dependent cell lines.
IL-2 also enhances the cytotoxicity of lymphocytes. Inductionof NK cell and lymphocyte-activated killer (LAK) cell activityoccurs, as does induction of production. In mouse andhuman tumor cell lines, aldesleukin activates cellular immunityin patients with profound lymphocytosis, eosinophilia,and thrombocytopenia. Aldesleukin also activates the productionof cytokines, including tumor necrosis factor (TNF),IL-1, and IFN-γ. In vivo experiments in mouse tumor modelshave shown inhibition of tumor growth. The mechanism ofthe antitumor effect of aldesleukin is unknown.
Aldesleukin is indicated for the treatment of metastaticrenal cell carcinoma in adults. It is also indicated for thetreatment of metastatic melanoma in adults. Research isunder way on the use of aldesleukin for the treatment of variouscancers (including head and neck cancers), treatment ofacute myelogenous leukemia, and adjunct therapy in thetreatment of Kaposi sarcoma. Renal and hepatic function istypically impaired during therapy with aldesleukin, so interactionwith other drugs that undergo elimination by these organsis possible.

???

Several serious toxicities have been observed, with a fatality rate of 5% in the initial studies. The major adverse effect is severe hypotension in as many as 85% of patients, which may lead to myocardial infarctions, pulmonary edema, and strokes.This hypotension is thought to be due to a capillary leak syndrome resulting from extravasation of plasma proteins and fluid into extravascular space and a loss of vascular tone. Patients with significant cardiac, pulmonary, renal, hepatic, or CNS conditions should not receive therapy with aldesleukin. Other adverse reactions include nausea and vomiting, diarrhea, stomatitis, anorexia, altered mental status, fevers, and fatigue.

HUMAN IL-2 ?? ?? ? ???

???

?? ??

HUMAN IL-2 ?? ??

???	??	???	??	?? ?	??
Career Henan Chemica Co	+86-0371-86658258 +8613203830695	laboratory@coreychem.com	China	30230	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	22854	58
	821-50328103-801 18930552037	3bsc@sina.com	China	15839	69
NCE Biomedical Co.,Ltd.	4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988		China	1493	55
LETOPHARM LIMITED	+86-21-5821 5861	sales@letopharm.com	China	2384	58
Chizhou Kailong Import and Export Trade Co., Ltd.		xg01_gj@163.com	China	9484	50
Sigma-Aldrich	021-61415566 800-8193336	orderCN@merckgroup.com	China	51456	80
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10356	58
Gongyishengan Technology (Shenzhen) Co., Ltd.	+86-0755-89218110 +86-13480856786	2880189130@qq.com	China	959	58
Shanghai Yaji Biological Technology Co., Ltd.	021-34661275 15301693058	yajikit@163.com	China	9747	58

HUMAN IL-2 ?? ??: